Anti-TERT/ CMM9/ DKCA2 monoclonal antibody
Anti-TERT/ CMM9/ DKCA2 antibody for FACS & in-vivo assay
Go to TERT/TERT products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T86052-Ab-1/ GM-Tg-hg-T86052-Ab-2 | Anti-Human TERT monoclonal antibody | Human |
GM-Tg-rg-T86052-Ab-1/ GM-Tg-rg-T86052-Ab-2 | Anti-Rat TERT monoclonal antibody | Rat |
GM-Tg-mg-T86052-Ab-1/ GM-Tg-mg-T86052-Ab-2 | Anti-Mouse TERT monoclonal antibody | Mouse |
GM-Tg-cynog-T86052-Ab-1/ GM-Tg-cynog-T86052-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TERT monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T86052-Ab-1/ GM-Tg-felg-T86052-Ab-2 | Anti-Feline TERT monoclonal antibody | Feline |
GM-Tg-cang-T86052-Ab-1/ GM-Tg-cang-T86052-Ab-2 | Anti-Canine TERT monoclonal antibody | Canine |
GM-Tg-bovg-T86052-Ab-1/ GM-Tg-bovg-T86052-Ab-2 | Anti-Bovine TERT monoclonal antibody | Bovine |
GM-Tg-equg-T86052-Ab-1/ GM-Tg-equg-T86052-Ab-2 | Anti-Equine TERT monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T86052-Ab-1/ GM-Tg-hg-T86052-Ab-2; GM-Tg-rg-T86052-Ab-1/ GM-Tg-rg-T86052-Ab-2; GM-Tg-mg-T86052-Ab-1/ GM-Tg-mg-T86052-Ab-2; GM-Tg-cynog-T86052-Ab-1/ GM-Tg-cynog-T86052-Ab-2; GM-Tg-felg-T86052-Ab-1/ GM-Tg-felg-T86052-Ab-2; GM-Tg-cang-T86052-Ab-1/ GM-Tg-cang-T86052-Ab-2; GM-Tg-bovg-T86052-Ab-1/ GM-Tg-bovg-T86052-Ab-2; GM-Tg-equg-T86052-Ab-1/ GM-Tg-equg-T86052-Ab-2 |
Products Name | Anti-TERT monoclonal antibody |
Format | mab |
Target Name | TERT |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TERT benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species TERT/ CMM9/ DKCA2 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAD000402 | human TERT Adenovirus plasmid |
ORF Viral Vector | vGMLV000557 | human TERT Lentivirus particle |
ORF Viral Vector | vGMLV000364 | human TERT Lentivirus particle |
ORF Viral Vector | vGMAD000402 | human TERT Adenovirus particle |
ORF Viral Vector | pGMLV000364 | human TERT Lentivirus plasmid |
ORF Viral Vector | pGMLV000557 | human TERT Lentivirus plasmid |
ORF Viral Vector | vGMLV000884 | human TERT Lentivirus particle |
ORF Viral Vector | pGMLV000009 | human TERT Lentivirus plasmid |
ORF Viral Vector | pGMLV000884 | human TERT Lentivirus plasmid |
ORF Viral Vector | vGMLV000009 | human TERT Lentivirus particle |
ORF Viral Vector | pGMAD000360 | rat Tert Adenovirus plasmid |
ORF Viral Vector | pGMAD000476 | Norway rat Tert Adenovirus plasmid |
ORF Viral Vector | vGMAD000360 | rat Tert Adenovirus particle |
ORF Viral Vector | vGMAD000476 | Norway rat Tert Adenovirus particle |
Target information
Target ID | GM-T86052 |
Target Name | TERT |
Gene ID | 7015,21752,301965,709865,403412,100144612,518884,100630695 |
Gene Symbol and Synonyms | CMM9,DKCA2,DKCB4,EST2,hEST2,hTRT,PFBMFT1,TCS1,TERT,TP2,TR,TRT |
Uniprot Accession | O14746,Q673L6,Q6A548,Q27ID4 |
Uniprot Entry Name | TERT_HUMAN,TERT_RAT,TERT_CANLF,TERT_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Cancer |
Gene Ensembl | ENSG00000164362 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: TERT, gene name: TERT, also named as CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT. Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by addition of the telomere repeat TTAGGG. The enzyme consists of a protein component with reverse transcriptase activity, encoded by this gene, and an RNA component which serves as a template for the telomere repeat. Telomerase expression plays a role in cellular senescence, as it is normally repressed in postnatal somatic cells resulting in progressive shortening of telomeres. Deregulation of telomerase expression in somatic cells may be involved in oncogenesis. Studies in mouse suggest that telomerase also participates in chromosomal repair, since de novo synthesis of telomere repeats may occur at double-stranded breaks. Alternatively spliced variants encoding different isoforms of telomerase reverse transcriptase have been identified; the full-length sequence of some variants has not been determined. Alternative splicing at this locus is thought to be one mechanism of regulation of telomerase activity. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.